You are here: Industry Insights > ADC

News List

MilliporeSigma Expands HPAPI and ADC Mfg. Capabilities contractpharma
September 18, 2020
$65 million investment to expand facility near Madison, WI will allow large-scale manufacturing of increasingly potent compounds.
Exelixis and Catalent Enter ADC Partnership contractpharma
September 17, 2020
Collaboration, license and exclusive option agreement to develop antibody-drug conjugates leveraging SMARTag bioconjugation technology.
Abzena Receives $10M Investment from Biospring Partners contractpharma
July 29, 2020
New capital will allow Abzena to further accelerate its growth plans. Abzena drove 80% revenue growth and tripled GMP manufacturing capacity in 1H20.
Trio Pharmaceuticals, Ajinomoto Bio-Pharma Announce Antibody Therapeutic Collaboration americanpharmaceuticalreview
May 04, 2020
Trio Pharmaceuticals and Ajinomoto Bio-Pharma Services announced a development collaboration agreement to evaluate AJICAP™.
OBI Pharma Granted Orphan Drug Designation for ADC Targeted Cancer Therapy americanpharmaceuticalreview
January 06, 2020
OBI Pharma announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-999 for the treatment of Pancreatic Cancer. OBI-999 is a first-in-class antibody drug conjugate targeting Globo H, a glycolipid antigen.
MabPlex Lauded by Frost & Sullivan for Global Expansion of ADC Contract Manufacturing Services En-CPhI.CN
October 12, 2019
Based on its recent analysis of the global antibody drug conjugate (ADC) contract manufacturing services market, Frost & Sullivan recognizes China-based MabPlex International ...
ADCendo secures loan to advance ADCs for cancer treatment pharmaceutical-technology
September 03, 2019
ADCendo has secured a loan amount to advance its novel antibody-drug conjugates (ADCs) that are being developed to treat cancers.
ADC Therapeutics, Freenome Enter Biomarker Development Collaboration contractpharma
August 29, 2019
ADC Therapeutics to employ Freenome's multiomics platform to identify biomarkers that correlate with clinical response to ADCT-402.
ADC Therapeutics, SOPHiA GENETICS Partner for Biomarker Discovery contractpharma
August 08, 2019
Pivotal Phase II trial to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in DLBCL.
Abzena Completes ADC Tech Transfer contractpharma
July 24, 2019
Successful technical transfer of Synaffix GlycoConnect ADC Technology to enable use in client projects.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page